☰

Matthew Kyle Hadden - Publications

Affiliations: 
University of Connecticut, Storrs, CT, United States 
Area:
Medicinal Chemistry
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Teske KA, Dash RC, Morel SR, Chau LQ, Wechsler-Reya RJ, Hadden MK. Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. European Journal of Medicinal Chemistry. 163: 320-332. PMID 30529635 DOI: 10.1016/J.Ejmech.2018.11.056  0.32
2012 DeBerardinis AM, Banerjee U, Miller M, Lemieux S, Hadden MK. Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway. Bioorganic & Medicinal Chemistry Letters. 22: 4859-63. PMID 22687748 DOI: 10.1016/J.Bmcl.2012.05.037  0.36
2009 Hadden MK, Blagg BS. Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. The Journal of Organic Chemistry. 74: 4697-704. PMID 19492825 DOI: 10.1021/jo900278g  0.597
2009 Orwig KS, Lassetter MR, Hadden MK, Dix TA. Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. Journal of Medicinal Chemistry. 52: 1803-13. PMID 19290594 DOI: 10.1021/Jm801072V  0.736
2009 Hadden MK, Hill SA, Davenport J, Matts RL, Blagg BS. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorganic & Medicinal Chemistry. 17: 634-40. PMID 19101151 DOI: 10.1016/J.Bmc.2008.11.064  0.568
2008 Hadden MK, Blagg BS. Dimeric approaches to anti-cancer chemotherapeutics. Anti-Cancer Agents in Medicinal Chemistry. 8: 807-16. PMID 18855582  0.473
2008 Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, Hornbaker K, Heckert LL, Ozturk SB, Hadden MK, Kinzy TG, Blagg BS, Georg GI. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biology of Reproduction. 78: 1139-52. PMID 18218611 DOI: 10.1095/Biolreprod.107.062679  0.567
2008 Hastings JM, Hadden MK, Blagg BS. Synthesis and evaluation of derrubone and select analogues. The Journal of Organic Chemistry. 73: 369-73. PMID 18154304 DOI: 10.1021/jo702366g  0.55
2007 Hadden MK, Galam L, Gestwicki JE, Matts RL, Blagg BS. Derrubone, an inhibitor of the Hsp90 protein folding machinery. Journal of Natural Products. 70: 2014-8. PMID 18020309 DOI: 10.1021/Np070190S  0.524
2007 Hadden MK, Blagg BS. Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells. Bioorganic & Medicinal Chemistry Letters. 17: 5063-7. PMID 17656092 DOI: 10.1016/j.bmcl.2007.07.014  0.519
2007 Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, Neckers L, Audus KL, Michaelis ML, Blagg BS. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorganic & Medicinal Chemistry Letters. 17: 1984-90. PMID 17276679 DOI: 10.1016/J.Bmcl.2007.01.017  0.747
2007 Galam L, Hadden MK, Ma Z, Ye QZ, Yun BG, Blagg BS, Matts RL. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorganic & Medicinal Chemistry. 15: 1939-46. PMID 17223347 DOI: 10.1016/J.Bmc.2007.01.004  0.576
2006 Hadden MK, Lubbers DJ, Blagg BS. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Current Topics in Medicinal Chemistry. 6: 1173-82. PMID 16842154 DOI: 10.2174/156802606777812031  0.548
2006 Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ, Blagg BS. High-throughput screening for Hsp90 ATPase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16: 3005-8. PMID 16530412 DOI: 10.1016/j.bmcl.2006.02.063  0.52
2005 Hadden MK, Orwig KS, Kokko KP, Mazella J, Dix TA. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology. 49: 1149-59. PMID 16095636 DOI: 10.1016/J.Neuropharm.2005.06.010  0.696
2005 Hadden MK, Walle T, Dix TA. Cellular uptake of a radiolabelled analogue of neurotensin in the Caco-2 cell model. The Journal of Pharmacy and Pharmacology. 57: 327-33. PMID 15807988 DOI: 10.1211/0022357055560  0.63
2005 Kokko KP, Hadden MK, Price KL, Orwig KS, See RE, Dix TA. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier. Neuropharmacology. 48: 417-25. PMID 15721174 DOI: 10.1016/J.Neuropharm.2004.10.008  0.697
2005 Hadden MK, Kokko KP, Dix TA. Asymmetric Synthesis of ω‐Bromo‐2(S)‐Methyl Acids as Precursors for Novel Arginine, Lysine, and Mercapto Residues Synthetic Communications. 35: 1675-1680. DOI: 10.1081/Scc-200061668  0.764
2005 Hadden MK, Kokko KP, Dix TA. Asymmetric Synthesis of ω-Bromo-2(S)-methyl Acids as Precursors for Novel Arginine, Lysine, and Mercapto Residues. Cheminform. 36. DOI: 10.1002/CHIN.200547188  0.735
2003 Kokko KP, Hadden MK, Orwig KS, Mazella J, Dix TA. In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues. Journal of Medicinal Chemistry. 46: 4141-8. PMID 12954066 DOI: 10.1021/Jm0300633  0.697
Show low-probability matches.